NClip

Anorexiants

4 min read

Anorexiants

Key Points

  • Anorexiants are appetite-suppressant stimulants used as adjunct therapy when sustained lifestyle-only weight-loss attempts are insufficient.
  • Core mechanism is enhanced norepinephrine signaling in hypothalamic appetite pathways, which suppresses appetite and can increase metabolic activity.
  • Major agents include phentermine, phentermine-topiramate ER, phendimetrazine, and benzphetamine.
  • Class safety priorities are cardiovascular stimulation, insomnia, misuse/dependence risk, and high-risk interaction screening.
  • All class agents are contraindicated with MAOI exposure within the prior 14 days.
  • Tolerance to appetite-suppressant effects can develop within weeks; clients should never self-increase dose.

Mechanism and Therapeutic Role

These drugs are sympathomimetic appetite suppressants that increase central norepinephrine availability, reducing hunger signals and supporting calorie-deficit adherence. They are used with dietary change and physical-activity plans, not as standalone long-term therapy.

Most regimens are short term (often 8-12 weeks), and continuation decisions should be tied to measurable weight-response thresholds and safety tolerance.

Drug Snapshot

DrugTypical Dosing PatternHigh-Yield RN Safety Points
Phentermine15-37.5 mg every morning, or selected formulations 8 mg three times dailyGive before meals (about 30 minutes prior or 1-2 hours after); avoid late-day dosing to reduce insomnia; Schedule IV
Phentermine-topiramate ERStart low-dose for 14 days, then daily titration with 12-week reassessmentIf response is inadequate, escalate or discontinue per protocol; taper high-dose discontinuation to lower seizure risk; Schedule IV
PhendimetrazineER/SR once daily before morning meal, or IR dosing before mealsSwallow ER/SR whole; do not crush/chew; stimulant adverse effects and misuse risk require surveillance
Benzphetamine25-50 mg 1-3 times daily, often single midday dosingAvoid dosing within 6 hours of bedtime; Schedule III; avoid in clients with addictive-behavior history

Indications and Client Selection

  • Use as adjunct to calorie restriction and exercise in obesity or overweight with comorbidity burden.
  • Typical pharmacologic thresholds include BMI 30 or greater, or BMI 27-29 with obesity-related comorbidities such as hypertension, type 2 diabetes, or dyslipidemia.
  • Screen carefully for contraindication history: cardiovascular disease, moderate-severe hypertension, hyperthyroidism, glaucoma, severe renal/hepatic impairment, pregnancy/lactation, and recent MAOI use.
  • Avoid or use extreme caution in clients with substance-use history because class drugs carry Schedule III/IV misuse potential.

Nursing Assessment

NCLEX Focus

First decide whether stimulant risk outweighs weight-loss benefit in this client, then prioritize interaction and contraindication screening before routine administration.

  • Assess baseline and trend weight, BMI, and obesity-related comorbidity burden.
  • Assess cardiovascular status (BP, HR, rhythm symptoms, chest pain, syncope, dyspnea) before and during therapy.
  • Screen full medication list for MAOIs, TCAs, SSRIs, stimulant combinations, and selected antihypertensives.
  • Assess mental-status and behavioral changes, including worsening depression or suicidal ideation, especially with phentermine-topiramate pathways.
  • In clients with diabetes, monitor for hypoglycemia risk as weight decreases and reinforce glucose-testing plan updates.
  • Assess adherence and possible dependence signals, including dose escalation requests and non-prescribed use behavior.

Nursing Interventions and Teaching

  • Administer stimulant anorexiants early in the day and before meals as ordered; avoid bedtime-proximal doses.
  • Reinforce that missed doses should not be doubled.
  • Reinforce structured weight monitoring (for example at least 3 times weekly with the same scale/time conditions).
  • Teach that medication must remain paired with nutrition/activity intervention; monitor objective response at protocol checkpoints.
  • For phentermine-topiramate ER, follow reassessment milestones (for example 12-week response thresholds) and taper high-dose discontinuation when ordered.
  • Instruct clients to report severe headache, palpitations, chest pain, dyspnea, syncope, severe rash, vision changes, agitation, or suicidal thoughts immediately.
  • Reinforce that ER/SR stimulant formulations should not be crushed, opened, or chewed.
  • Reinforce pregnancy avoidance for contraindicated agents and escalate immediately if pregnancy is suspected.

MAOI Interaction

Do not give anorexiants if MAOIs were used in the prior 14 days due to severe adverse reaction risk.

Cardiovascular Stimulant Risk

Sympathomimetic stimulation can trigger tachycardia, hypertension, arrhythmia, ischemia, and other serious events in susceptible clients.

Withdrawal and Seizure Risk

Abrupt discontinuation of phentermine-topiramate (topiramate component) can precipitate seizures; follow taper instructions for high-dose regimens.

Clinical Judgment Application

Clinical Scenario

A client with BMI 34, hypertension, and type 2 diabetes starts phentermine-topiramate ER after unsuccessful lifestyle-only treatment.

  • Recognize Cues: Stimulant therapy in a client with cardiometabolic comorbidities and polypharmacy.
  • Analyze Cues: Benefit may be meaningful, but interaction, BP/HR effects, mood changes, and glucose shifts are priority risks.
  • Prioritize Hypotheses: Highest immediate risk is stimulant-related adverse effects with preventable harm if monitoring is delayed.
  • Generate Solutions: Set early follow-up for vitals/weight response, review interacting drugs, and reinforce warning-sign reporting.
  • Take Action: Perform focused cardiovascular and behavioral assessment and verify adherence to dosing/timing and lifestyle plan.
  • Evaluate Outcomes: Weight-response targets are met without severe adverse effects, and safety-monitoring adherence is sustained.

Graph View

Backlinks